Noxopharm Ltd. (AU:NOX)
ASX:NOX
Want to see AU:NOX full AI Analyst Report?
NOX Stock Chart & Stats
AU$0.09
>-AU$0.01(-8.99%)
At close: 4:00 PM EST
AU$0.09
>-AU$0.01(-8.99%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.14
Previous CloseN/A
Volume154.85K
Average Volume (3M)123.50K
Market Cap
AU$19.66M
Enterprise ValueAU$23.82M
Total Cash (Recent Filing)AU$1.55M
Total Debt (Recent Filing)AU$2.48M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding307,237,950
10 Day Avg. Volume89,571
30 Day Avg. Volume123,503
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)22.89
Price to Sales (P/S)5.60
P/FCF Ratio-2.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Oncology R&D PipelineNoxopharm's clear strategic focus on oncology drug R&D targeting enhanced anti-tumor immune responses and improving existing cancer treatments is a durable fundamental strength. A concentrated pipeline in oncology can produce high-value assets and strategic partnerships over 2-6 months as trials progress and data readouts occur.
2025 Revenue ReboundRevenue recovering by roughly 20% in 2025 signals improving commercial traction or milestone-driven receipts versus prior declines. If sustained, this trend supports scale in operations, demonstrates progressing business development, and helps validate elements of the business model beyond one-off funding events.
Improving Free Cash Flow TrendAn improvement in free cash flow year-over-year, even from negative levels, indicates operational efficiencies or timing of receipts improving the cash profile. Continued improvement reduces the pace of external funding needs and extends runway, strengthening financial flexibility over the medium term.
Bears Say
Weakened Balance Sheet And High LeverageMaterial balance-sheet deterioration with debt roughly 3.6x equity sharply reduces financial flexibility. High leverage increases refinancing and interest risk, constrains the company's ability to fund R&D internally, and raises the likelihood of dilutive or costly external financing if the funding gap persists.
Persistent Cash BurnConsistent negative operating and free cash flow indicates the business is not self-funding and relies on external capital. Persistent cash burn elevates dilution and refinancing risk, limits sustained investment in development programs, and makes the company sensitive to capital market conditions over the medium term.
Ongoing Unprofitability And Negative Gross ProfitNegative gross profit and substantial operating losses show the core operations are not yet economically viable. Deeply negative margins and persistently negative net results undermine returns on equity and indicate the company must materially improve cost structure, achieve higher revenue, or secure non-dilutive funding to reach sustainable profitability.
Noxopharm Ltd. News
NOX FAQ
What was Noxopharm Ltd.’s price range in the past 12 months?
Noxopharm Ltd. lowest share price was AU$0.04 and its highest was AU$0.14 in the past 12 months.
What is Noxopharm Ltd.’s market cap?
Noxopharm Ltd.’s market cap is AU$19.66M.
When is Noxopharm Ltd.’s upcoming earnings report date?
Noxopharm Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 97 days.
How were Noxopharm Ltd.’s earnings last quarter?
Noxopharm Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.006.
Is Noxopharm Ltd. overvalued?
According to Wall Street analysts Noxopharm Ltd.’s price is currently Overvalued.
Does Noxopharm Ltd. pay dividends?
Noxopharm Ltd. does not currently pay dividends.
What is Noxopharm Ltd.’s EPS estimate?
Noxopharm Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Noxopharm Ltd. have?
Noxopharm Ltd. has 307,237,950 shares outstanding.
What happened to Noxopharm Ltd.’s price movement after its last earnings report?
Noxopharm Ltd. reported an EPS of -AU$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.538%.
Which hedge fund is a major shareholder of Noxopharm Ltd.?
Currently, no hedge funds are holding shares in AU:NOX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Noxopharm Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.50%
12-Months-Change
Fundamentals
Return on Equity
2509.60%
Trailing 12-Months
Asset Growth
-13.13%
Trailing 12-Months
Company Description
Noxopharm Ltd.
Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Technical Analysis
Prescient Therapeutics Limited
―
Chimeric Therapeutics Ltd.
―
EZZ Life Science Holdings Ltd.
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―